Clear Cell Squamous Cell Carcinoma of the Maxillary Gingiva Associated with PIK3CA and HRAS Mutations: Report of a Case and Literature Review

Background Squamous cell carcinoma (SCC) is the most common oral malignancy, and somatic mutations in some driver genes have been implicated in SCC development. Clear cell SCC (CCSCC) is a rare histological variant of SCC, and various clear cell neoplasms must be considered in the differential diagnosis of CCSCC in the oral cavity. Based on a limited number of CCSCC cases reported in the oral cavity, CCSCC is considered an aggressive variant of SCC with a poor prognosis; however, its genetic characteristics remain unknown. Methods A maxillary gingival tumor in an 89-year-old female was described and investigated using immunohistochemical staining, special staining, fluorescence in situ hybridization, and next-generation sequencing (NGS) with a custom panel of driver genes, including those associated with SCC and clear cell neoplasm development. Results Histopathological examination revealed a proliferation of atypical epithelial cells with abundant clear cytoplasm and enlarged and centrally placed round nuclei. The tumor was exophytic with deep, penetrating proliferation. The atypical clear cells were continuous with the conventional SCC cells. Immunohistochemical analysis showed that the clear cells were positive for CK AE1/AE3 and CK5/6 and nuclear-positive for p63. In contrast, the clear cells were negative for αSMA, S100, HMB45, Melan-A, CD10, and p16. p53 immunoreactivity exhibited a wild-type expression pattern. Additionally, the clear cells were positive for periodic acid-Schiff (PAS) and negative for diastase-PAS, mucicarmine, and Alcian blue. Based on these results, the diagnosis of CCSCC was confirmed. Molecular analysis of the clear cells identified PIK3CA p.E542K (c.1624G>A) and HRAS p.G12A (c.35 G>C) somatic mutations classified as oncogenic. No pathogenic variants were identified in TP53, EWSR1, AKT1, PTEN, BRAF, KRAS, NRAS, RASA1, or MAML2. Conclusions We report a case of CCSCC of the oral cavity with PIK3CA and HRAS mutations. The identification of PIK3CA and/or HRAS mutations is rare in SCC; however, both mutations are important potential targets for antitumor therapy. A detailed analysis of gene mutations in CCSCC may lead to a better understanding of its biological behavior and an improved prognosis, as well as a differential diagnosis from other clear cell neoplasms.

Activation of phosphatidylinositol 3-kinase (PI3K)/ AKT and RAS/RAF signaling pathways, which regulate cell proliferation and growth, apoptosis, autophagy, invasion, and migration, is observed in various malignancies, including SCC [17,18].Mutations in the genes involved in signaling pathways are closely related to cancer development and prognosis [17,18].Currently, efforts are focused on understanding the molecular and cellular consequences of these mutations and the opportunities for targeted therapies [18][19][20][21].Detailed analysis of genetic mutations in pathways involving potential targets for antitumor therapy may lead to an improved prognosis for CCSCC.However, no reports identifying genetic mutations in CCSCC exist, and the genetic characteristics are still unknown.Moreover, various clear cell neoplasms may be found in the oral cavity, which must be considered in the differential diagnosis of CCSCC [6].These clear cell neoplasms that are independent of SCC have well-defined genetic profiles that may help specify diagnoses in difficult cases (Table 2).Here, we report a case of CCSCC of the maxillary gingiva with PIK3CA and HRAS mutations and review the literature on CCSCC of the oral cavity.

Clinical Summary
An 89-year-old female was referred to the Osaka University Dental Hospital for painful swelling in the upper right gingival region.The patient had noticed a gingival mass for 1 month and had no significant medical history.Intraoral examination revealed an approximately 60 × 40 mm lobulated mass with an ulcerative surface on the right maxillary posterior gingiva extending to the buccal mucosa (Fig. 1a).Computed tomography (CT) revealed an infiltrative lesion with maxillary bone resorption (Fig. 1b, c).With a provisional diagnosis of SCC, an incisional biopsy was performed (Fig. 2) followed by segmental maxillectomy (Fig. 3).The tumor recurred after 3 months, and the patient died 8 months after surgery due to complications related to disease recurrence (Table 1).

Pathological Findings
Biopsy showed an infiltrative neoplasm (Fig. 2a).The tumor was primarily exophytic but with a pattern of deep, pushing invasion with keratin debris in crypt spaces (Fig. 2a, b).Tumor cells had prominent clear cytoplasm, especially from the parabasal cells to the surface epithelium (Fig. 2c).Clear cells exhibited enlarged, centrally placed, round nuclei (Fig. 2d).Nuclear and cellular atypia of tumor cells were observed (Fig. 2d).Based on these observations, a clear-cell variant of SCC was suspected, and subsequent segmental maxillectomy was performed (Fig. 3a).Histopathological examination of the surgical specimen affirmed biopsy findings.Additionally, sheets and islands of atypical clear cells infiltrated deep connective tissues (Fig. 3b).The clear cells were contiguous with conventional SCC cells connected to the normal epithelium (Fig. 3c-f), indicating the clear cells to be a component of the SCC.Clear cells accounted for a majority (80%) of tumor cells (Fig. 3a).Conventional SCC extended from the oral surface to the maxillary sinus with bone resorption (Fig. 3c).We did not perform immunohistochemical staining, special staining, or molecular analysis of the conventional SCC since the conventional SCC was observed only in formalin-fixed paraffin-embedded (FFPE) samples containing bone and decalcified by formic acid (Fig. 3c).Immunohistochemical analysis showed that the clear cells were positive for both CK AE1/AE3 (Fig. 4a) and CK5/6 mainly in the upper half of the epithelial layers, and were nuclear-positive for p63 in all epithelial layers (Fig. 4b).In contrast, the clear cells were negative for αSMA, S100, HMB45, Melan-A, CD10, and p16.The clear cells exhibited a p53 wild-type expression pattern (negative to weakly positive) (Fig. 4d).Immunohistochemical evaluation of Ki-67 revealed nuclear staining, mostly in the basal and parabasal cells of the atypical epithelium (Fig. 4c).Additionally, the cytoplasm of the clear cells was positive for periodic acid-Schiff (PAS) and negative for diastase-PAS, mucicarmine, and Alcian blue, suggesting accumulation of glycogen in the cytoplasm of the atypical clear cells (Fig. 4e-h).
Postoperative positron emission tomography (PET) CT was performed to assess distant metastasis.No signs of tumors were detected in other organs.Therefore, the

Discussion
CCSCC of the oral cavity is rare, and its genetics relative to conventional SCC are unclear.To date, only 12 cases of CCSCC in the oral cavity have been reported, including our case [4,[7][8][9][10][11][12][13][14][15][16].Previous reports have described that, histologically, CCSCC cells show abundant clear cytoplasm along with enlarged and centrally placed round nuclei [7,[9][10][11]14].It has been suggested that the proportion of clear cells required to define CCSCC is > 25% [2,5].Our case was consistent with the definition of CCSCC, both in the cytopathological findings and the proportion of clear cells in the lesion.Thus, our case is the first case of CCSCC, to our knowledge, in which a gene mutation has been described.
In the oral cavity, it is necessary to distinguish CCSCC from other tumors composed of clear cells: salivary gland carcinomas (clear cell variant mucoepidermoid carcinoma, clear cell myoepithelial carcinoma, and hyalinizing clear cell carcinoma [HCCC]), odontogenic carcinoma (clear cell odontogenic carcinoma [CCOC]), malignant melanoma, and metastatic carcinoma [6,23] (Table 2).The lack of intracellular mucin, confirmed by d-PAS, mucicarmine, and Alcian blue staining results, excluded the diagnosis of mucoepidermoid carcinoma [6].The lack of myoepithelial markers (such as SMA and S100) excluded clear-cell myoepithelial carcinoma [6].The tumor location on the oral surface and the histology of squamous differentiation excluded HCCC and CCOC [6,23].The lack of S100, Melan-A, and HMB45 immunoreactivity excluded malignant melanoma [6,23].Metastatic tumors, such as clear cell renal cell carcinoma (CCRCC), were excluded because there were no signs of tumors in the other organs and CD10 immunoreactivity was absent [6].These pathological and clinical findings led to the diagnosis of CCSCC in our case.Besides, our case of CCSCC was genetically different from other clear cell neoplasms in that MAML2 rearrangement (characteristic of mucoepidermoid carcinoma), EWSR1 rearrangement/translocation (characteristics of clear cell variants of myoepithelial carcinoma, HCCC, and CCOC), and BRAF mutations (detected in malignant melanoma and odontogenic tumors) were not detected (Table 2) [6,23].On the other hand, both PIK3CA (p.E542K) and HRAS (p.G12A) oncogenic mutations were detected, which are hardly detected in SCC (Fig. 5a, b) [1].Thus, genetically, CCSCC may be an entity of SCC and distinct from other clear cell neoplasms in the oral cavity.
Several PI3K/AKT and RAS/RAF targeting agents are currently undergoing clinical trials, and molecular profiling of these targets needs to be investigated [17][18][19][20][21].A recent study demonstrated that tipifarnib, a farnesyltransferase inhibitor that disrupts HRAS function, dramatically improved clinical outcomes in patients with HRAS-mutant HNSCC [21].Moreover, PI3K inhibitors have demonstrated antiproliferative, pro-apoptotic, and antitumor activities in a range of preclinical cancer models as a single agent or in combination with other anticancer therapies [19,20].CCSCC of the oral cavity is considered an SCC variant [8,11,[13][14][15].Thus, the PI3K/AKT and RAS/RAF pathways may be important potential targets for future therapeutic options in patients with CCSCC.

Conclusion
In conclusion, we report a case of CCSCC in the oral cavity associated with PIK3CA and HRAS mutations, potential targets for antitumor therapy.A detailed analysis of gene mutations in CCSCC may lead to a better understanding of its biological behavior and an improved prognosis, as well as distinguish CCSCC from other clear cell neoplasms.
were made.The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit http:// creat iveco mmons.org/ licen ses/ by/4.0/.

Fig. 1 Fig. 2
Fig. 1 Clinical presentation.a Intraoral finding.Representative coronal computed tomography (CT) images with bone window (b) and with contrast-enhanced (c).The blue arrows indicate a large tumor extension (b).The red arrow indicates a bone penetration at the alveolar process of the right maxilla (c)

Fig. 3
Fig. 3 Histological findings of the surgical specimen.a Gross view of the surgical specimen.b Region of clear cell squamous cell carcinoma (CCSCC).CCSCC infiltrated deep connective tissue (inset: cytology of CCSCC).c, d Transitional area between CCSCC (left side) and conventional squamous cell carcinoma (SCC) (right side).c shows the orange lined-box area in a. d shows the black dotted-box area in c. e, f Region of CCSCC or SCC in the transitional area (both from the black dotted-box area in d)

Table 1
Clinical characteristics of clear cell squamous cell carcinoma cases in the oral cavity origin F female, M male, + positive, − negative, N/A data not available, LN lymph node

Table 2
Staining panel and molecular findings for the differential diagnosis of clear cell neoplasms in the oral cavity